[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 24, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 64, "title": "Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 570990, "exercisedValue": 0, "unexercisedValue": 11528577}, {"maxAge": 1, "name": "Ms. Lourie S. Zak", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 346195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 66, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 54, "title": "General Counsel & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 52, "title": "Senior Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 78, "title": "Chief Medical Officer", "yearBorn": 1945, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 66, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.43, "open": 4.39, "dayLow": 4.1014, "dayHigh": 4.65, "regularMarketPreviousClose": 4.43, "regularMarketOpen": 4.39, "regularMarketDayLow": 4.1014, "regularMarketDayHigh": 4.65, "forwardPE": -3.6169116, "volume": 217499, "regularMarketVolume": 217499, "averageVolume": 203698, "averageVolume10days": 359430, "averageDailyVolume10Day": 359430, "bid": 4.23, "ask": 4.37, "bidSize": 100, "askSize": 100, "marketCap": 153004016, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 9.789, "priceToSalesTrailing12Months": 19125.502, "fiftyDayAverage": 2.8454, "twoHundredDayAverage": 2.6792, "currency": "USD", "enterpriseValue": 49052044, "floatShares": 25632872, "sharesOutstanding": 34538200, "sharesShort": 1433454, "sharesShortPriorMonth": 1118774, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.041500002, "heldPercentInsiders": 0.16284999, "heldPercentInstitutions": 0.15701, "shortRatio": 8.9, "shortPercentOfFloat": 0.049200002, "impliedSharesOutstanding": 35748600, "bookValue": 0.739, "priceToBook": 5.7916102, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -26538000, "trailingEps": -0.91, "forwardEps": -0.94, "enterpriseToRevenue": 6131.506, "enterpriseToEbitda": -1.819, "52WeekChange": -0.5044743, "SandP52WeekChange": 0.21027291, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.28, "targetHighPrice": 30.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.4, "targetMedianPrice": 19.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 33636000, "totalCashPerShare": 0.986, "ebitda": -26965000, "totalDebt": 2207000, "quickRatio": 5.796, "currentRatio": 6.009, "totalRevenue": 8000, "debtToEquity": 5.859, "returnOnAssets": -0.44608003, "returnOnEquity": -0.88571, "grossProfits": 8000, "freeCashflow": -11902625, "operatingCashflow": -21445000, "grossMargins": 1.0, "operatingMargins": -3414.375, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]